Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schmitz, F.-J.
Right arrow Articles by Fluit, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmitz, F.-J.
Right arrow Articles by Fluit, A. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 283-287
© 2002 The British Society for Antimicrobial Chemotherapy

Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus

Franz-Josef Schmitza,b,*, Mechthild Boosa, Susanne Mayera, Harold Jaguscha and Ad C. Fluitb

a Institute for Medical Microbiology and Virology, Heinrich-Heine University Düsseldorf, Germany; b Eijkman-Winkler Institute for Medical Microbiology, Utrecht University, The Netherlands

The in vitro activities of the novel des-fluoro(6) quinolone BMS-284756, ciprofloxacin, gatifloxacin and moxifloxacin were tested against 248 genetically defined Staphylococcus aureus isolates, comprised of 116 unrelated S. aureus, seven heterogeneous vancomycin-intermediate S. aureus (hetero-VISA) strains and 125 clonally related MRSA. All strains were susceptible to BMS-284756 at an investigational breakpoint of 1 mg/L. Reserpine did not decrease the MIC of BMS-284756 in any of the strains tested. The novel des-fluoro(6) quinolone BMS-284756 showed a significantly increased anti-staphylococcal activity.

* Correspondence address. Institute for Medical Microbiology and Virology, Heinrich-Heine-Universität Düsseldorf, Universitätsstraße 1, Geb. 22.21, 40225 Düsseldorf, Germany. Tel: +49-2132-72040; Fax: +49-2132-72040; E-mail: schmitfj{at}uni-duesseldorf.de


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
K. J. Christiansen, J. M. Bell, J. D. Turnidge, and R. N. Jones
Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001
Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2049 - 2055.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
X. Zhao, W. Eisner, N. Perl-Rosenthal, B. Kreiswirth, and K. Drlica
Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus
Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1023 - 1027.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.